3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
26
Leukemia, Lymphocytic, Chronic, B-Cell
24
Neoplasms
8
Leukemia
4
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Chromosome 17 deletion
3
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, Mantle-Cell
2
Leukemia, B-Cell
2
Venentoclax
1
Tumor Lysis Syndrome
1
Pathologic Complete Response
1
Lymphoma, B-Cell
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Interventions
Cyclophosphamide
3
Epirubicin
2
Docetaxel
2
Carboplatin
2
Capecitabine
2
Azacitidine
2
venetoclax
1
tegafur-gimeracil-oteracil
1
taxane
1
sargramostim
1
ruxolitinib
1
rucaparib
1
pirarubicin
1
pertuzumab
1
pembrolizumab
1
olaparib
1
cc-486
1
Trastuzumab
1
Thalidomide
1
Radiotherapy
1
Radiation
1
Platinum
1
Paclitaxel
1
Oxaliplatin
1
Observation
1
Nivolumab
1
Monatide (IMS 3015)
1
Methotrexate
1
Magnetic Resonance Imaging
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Pathologic Complete Response
×
venetoclax
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled